Real-World Evidence With Five-Year Data (2017-2022) on the use of Cladribine Tablets in Patients With Multiple Sclerosis in England: An Updated Analysis From the CLARENCE Study

被引：0

作者：

Brownlee, Wallace ^{[1
]}

Amin, Amerah ^{[2
]}

Ashton, Luke ^{[2
]}

Herbert, Alex ^{[2
]}

机构：

[1] UCL Inst Neurol, Queen Sq MS Ctr, London, England

[2] Merck Serono Ltd, Merck KGaA, Feltham, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1558/603

引用

页码：993 / 994

页数：2

共 50 条

[21] Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up [J].

Xu, Huimin ;

Ping, Yanting ;

Lin, Haoran ;

He, Ping ;

Li, Wenlu ;

Dai, Haibin .

TRANSLATIONAL STROKE RESEARCH, 2017, 8 (03) :228-233

[22] Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing [J].

Manni, A. ;

Oggiano, F. ;

Palazzo, C. ;

Panetta, V. ;

Gargano, C. D. ;

Mangialardi, V. ;

Guerra, T. ;

Iaffaldano, A. ;

Caputo, F. ;

Iaffaldano, P. ;

Ruggieri, M. ;

Trojano, M. ;

Paolicelli, D. .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 462

[23] Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study [J].

Gupta, Milan ;

Wani, Rajvi J. ;

Al Faraidy, Khalid ;

Bergeron, Jean ;

Contreras, Eduardo ;

Pena, Angel Alberto Garcia ;

Mancini, G. B. John ;

Padilla, Francisco ;

Lopez, Abel Alberto Pavia ;

Philip, Kiran ;

Wu, Johnny ;

Mackinnon, Erin S. .

CARDIOLOGY AND THERAPY, 2023, 12 (04) :703-722

[24] Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study [J].

Milan Gupta ;

Rajvi J. Wani ;

Khalid Al Faraidy ;

Jean Bergeron ;

Eduardo Contreras ;

Angel Alberto Garcia Peña ;

G. B. John Mancini ;

Francisco Padilla ;

Abel Alberto Pavia Lopez ;

Kiran Philip ;

Johnny Wu ;

Erin S. Mackinnon .

Cardiology and Therapy, 2023, 12 :703-722

[25] Switching patients with multiple sclerosis from anti-CD20 or S1P receptor modulators to cladribine tablets in the United States: A real-world age-based analysis [J].

Kutz, Christen ;

Aldridge, Julie ;

Evans, Emily ;

Jackson, Leila .

MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) :1091-1091

[26] Long-term clinical outcomes of patients treated with elosulfase alfa: Five-year real-world results from the Morquio A Registry Study (MARS) [J].

Mitchell, John ;

Ramaswami, Uma ;

Longo, Nicola ;

Chien, Yin-Hsiu ;

Guffon, Nathalie ;

Hwu, Wuh-Liang ;

Lauw, Michael ;

Ngu, Lock Hock ;

Pan, Wayne ;

Burton, Barbara .

MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) :S112-S112

[27] Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Analysis of Economic Data from the CLARITY Study [J].

Ali, Shehzad ;

Paracha, Noman ;

Cook, Stuart ;

Giovannoni, Gavin ;

Comi, Giancarlo ;

Rammohan, Kottil ;

Rieckmann, Peter ;

Sorensen, Per Soelberg ;

Vermersch, Patrick ;

Greenberg, Steven ;

Scott, David A. ;

Joyeux, Alexandre .

CLINICAL DRUG INVESTIGATION, 2012, 32 (01) :15-27

[28] The effect of alemtuzumab treatment in relapsing remitting multiple sclerosis: real-world data from a four-year prospective one center study [J].

Sandgren, S. ;

Novakova, L. ;

Axelsson, M. ;

Malmestrom, C. ;

Lycke, J. ;

Zetterberg, H. .

MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) :555-556

[29] Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study [J].

Leleu, Xavier ;

Slama, Borhane ;

Zambello, Renato ;

Badelita, Sorina Nicoleta ;

Katodritou, Eirini ;

Caers, Jo ;

Kuhr, Thomas ;

Suzan, Florence ;

Mohammad, Abeera ;

Wetten, Sally ;

Terpos, Evangelos .

BLOOD, 2020, 136

[30] Benefits of cladribine tablets on the achievement of no evidence of disease activity (NEDA) status in patients with multiple sclerosis: analysis of pooled double-blind data from the CLARITY and ONWARD studies [J].

Giovannoni, G. ;

Montalban, X. ;

Hicking, C. ;

Dangond, F. .

MULTIPLE SCLEROSIS JOURNAL, 2016, 22 :303-304

← 1 2 3 4 5 →